Identification of Potential Sepsis Therapeutic Drugs Using a Zebrafish Rapid Screening Approach
Life · 20.12.2024 · 14 (12) · 1689
DOI: 10.3390/life14121689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life, online erschienen am 20.12.2024. Verfasst von Mark Widder und 13 weiteren Autor:innen. Beteiligte Einrichtung: Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Army Medical Research and Development Command, United States Army Medical Research and Development Command, Military Infectious Disease Research Program.
Themen: Sepsis
Abstract (Originalsprache)
In the military, combat wound infections can progress rapidly to life-threatening sepsis. The discovery of effective small-molecule drugs to prevent and/or treat sepsis is a priority. To identify potential sepsis drug candidates, we used an optimized larval zebrafish model of endotoxicity/sepsis to screen commercial libraries of drugs approved by the U.S. Food and Drug Administration (FDA) and other active pharmaceutical ingredients (APIs) known to affect pathways implicated in the initiation and progression of sepsis in humans (i.e., inflammation, mitochondrial dysfunction, coagulation, and apoptosis). We induced endotoxicity in 3- and 5-day post fertilization larval zebrafish (characterized by mortality and tail fin edema (vascular leakage)) by immersion exposure to 60 µg/mL Pseudomonas aeruginosa lipopolysaccharide (LPS) for 24 h, then screened for the rescue potential of 644 selected drugs at 10 µM through simultaneous exposure to LPS. After LPS exposure, we used a neurobehavioral assay (light-dark test) to further evaluate rescue from endotoxicity and to determine possible off-target drug side effects. We identified 29 drugs with > 60% rescue of tail edema and mortality. Three drugs (Ketanserin, Tegaserod, and Brexpiprazole) produced 100% rescue and did not differ from the controls in the light-dark test, suggesting a lack of off-target neurobehavioral effects. Further testing of these three drugs at a nearly 100% lethal concentration of Klebsiella pneumoniae LPS (45 µg/mL) showed 100% rescue from mortality and 88–100% mitigation against tail edema. The success of the three identified drugs in a zebrafish endotoxicity/sepsis model warrants further evaluation in mammalian sepsis models.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
- General Dynamics Information Technology, Falls Church, VA 22042, USA.
- Culmen International, LLC, Alexandria, VA 22314, USA.
- Audie L. Murphy VA Medical Center, San Antonio, TX 78229, USA.
ORCID-Profile: Mark Widder, Ashley Moore, Robert Campbell, Kevin Akers, Michael Madejczyk, Blair Dancy
Förderung
- United States Army Medical Research and Development Command
- United States Army Medical Research and Development Command, Military Infectious Disease Research Program
Zitieren
APA
Widder, M., Carbaugh, C., van der Schalie, W., Miller, R., Brennan, L., Moore, A., Campbell, R., Akers, K., Ressner, R., Martin, M., Madejczyk, M., Dancy, B., Lee, P., & Lanteri, C. (2024). Identification of Potential Sepsis Therapeutic Drugs Using a Zebrafish Rapid Screening Approach. Life, 14(12), 1689. https://doi.org/10.3390/life14121689
Vancouver
Widder M, Carbaugh C, van der Schalie W, Miller R, Brennan L, Moore A, et al. Identification of Potential Sepsis Therapeutic Drugs Using a Zebrafish Rapid Screening Approach. Life. 2024;14(12):1689. doi:10.3390/life14121689
BibTeX
@article{Widder2024,
author = {Widder, Mark and Carbaugh, Chance and van der Schalie, William and Miller, Ronald and Brennan, Linda and Moore, Ashley and Campbell, Robert and Akers, Kevin and Ressner, Roseanne and Martin, Monica and Madejczyk, Michael and Dancy, Blair and Lee, Patricia and Lanteri, Charlotte},
title = {Identification of Potential Sepsis Therapeutic Drugs Using a Zebrafish Rapid Screening Approach},
journal = {Life},
year = {2024},
volume = {14},
number = {12},
pages = {1689},
doi = {10.3390/life14121689}
}
EUVIMED